Business · Companies · 8 hrs ago
Swiss officials and drugmakers dispute whether US price plans threaten medicine access
US President Donald Trump wants lower medicine prices, and the pharmaceutical industry says this could put pressure on prices in Switzerland.
Swiss price watchdog Stefan Meierhans and industry leader Marcel Plattner disagree about what that means for patients.
Plattner says US plans could make companies less willing to launch medicines in Switzerland, because some prices there may affect prices in the US.
Meierhans says the plans are uncertain, and Switzerland is not among the lowest-priced countries in two of the US programmes he discusses.
The two sides also dispute how many new medicines are reaching Swiss patients: Plattner says 35 per cent of innovative products were available in Switzerland, compared with 58 per cent in Germany and 88 per cent in the US.
He says companies plan to delay eight product launches in Switzerland in 2026 and have cancelled three.
Meierhans says claims that US plans will reduce access are still speculation, since the programmes and company agreements remain unclear.
The dispute matters because delayed launches could limit patients' access to new treatments.
The effect on Swiss medicine access remains uncertain, as the US plans and legal challenge are unresolved.
Swiss price supervisor Stefan Meierhans and pharmaceutical industry representative Marcel Plattner disagree over whether US drug-price plans threaten medicine access in Switzerland.
Plattner says US plans could discourage companies from launching medicines in Switzerland because Swiss prices may affect prices in the United States.
Meierhans says the plans’ effects are unclear and argues that price is not the only factor affecting access.
Plattner says eight products will not initially be introduced in Switzerland in 2026, and three launches have been cancelled.
He also says innovative products were available in the United States at a higher rate than in Germany or Switzerland in recent years.
- Who
- Swiss price supervisor Stefan Meierhans and Marcel Plattner, president of the pharmaceutical association Vips.
- What
- They disagree over whether US plans to lower medicine prices could reduce medicine access in Switzerland.
- When
- The article was published on November 21, 2026. Plattner says eight products will not initially be introduced in Switzerland in 2026.
- Where
- Switzerland and the United States.
- Why
- US plans may link American prices to prices in selected countries, including Switzerland; Plattner says this could discourage launches, while Meierhans says the impact is uncertain.
Stefan Meierhans
Marcel Plattner
Effect of US plans
Stefan Meierhans
The effects on Switzerland are uncertain, and it is not known whether the programs will be implemented or what the agreements contain.
Marcel Plattner
The plans could make companies less willing to launch medicines in Switzerland.
Factors affecting access
Stefan Meierhans
Price is not the only factor affecting how quickly patients get access; strategic considerations also matter.
Marcel Plattner
Price is an important factor, and Switzerland is already behind other countries in access to innovative products.
Swiss prices
Stefan Meierhans
Swiss prices are not necessarily among the lowest in the countries considered by some US models; Meierhans rejects adjusting international prices for purchasing power.
Marcel Plattner
After discounts and accounting for Swiss purchasing power, prices in Switzerland are relatively low.
Plattner says 88 percent of innovative products were available in the United States, compared with 58 percent in Germany and 35 percent in Switzerland.
Plattner says companies will not initially introduce eight products in Switzerland and have cancelled the launch of three.
NZZ published the discussion between Meierhans and Plattner about US drug-price plans and Swiss access.
- US price program
- The “Most favored nation” program described by Plattner includes G-7 countries, Denmark and Switzerland.
- Innovative products available
- United States: 88%; Germany: 58%; Switzerland: 35%.
- Products not initially introduced
- Eight products in Switzerland in 2026, according to Plattner.
- Launches cancelled
- Three product launches in Switzerland, according to Plattner.
- Annual market launches
- Plattner says 50 to 60 products come to market each year.
What people are saying
We cannot estimate how large the effects on Switzerland will be.
The price is not the only thing that determines how quickly you get access to a medicine.
For 2026, we see that our companies will not initially introduce eight products.
In the United States, 88 percent of all innovative products were available in recent years. In Germany it was 58 percent, and in Switzerland just 35 percent.